Clinical Trials Logo

Erectile Dysfunction clinical trials

View clinical trials related to Erectile Dysfunction.

Filter by:

NCT ID: NCT05043896 Completed - Clinical trials for Erectile Dysfunction

The Effect of Combination Therapy Using Li-ESWT and PDE-5 Inhibitor in Patients With Erectile Dysfunction

Start date: December 10, 2019
Phase: N/A
Study type: Interventional

to compare the effect of combination of li-eswt and pde-5 inhibitor to pde-5 alone in erectile dysfunction patients

NCT ID: NCT04984993 Completed - Clinical trials for Erectile Dysfunction

Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

Start date: September 14, 2021
Phase: Phase 3
Study type: Interventional

An open-label investigation using MED3000 gel or tadalafil (5 mg) tablets in the treatment of erectile dysfunction in patients from 22 to 70 years of age. Each patients will be expected to participate for up to 30 weeks. Eligible patients will be randomised to receive either MED3000 gel or tadalafil (5 mg) tablets in a 1:1 ratio.

NCT ID: NCT04980508 Completed - Covid19 Clinical Trials

Effects of COVID-19 on Cavernous Smooth Muscle

Start date: February 20, 2021
Phase: N/A
Study type: Interventional

The aim of the study is to illuminate the role of COVID-19 in the pathophysiology of erectile dysfunction (ED). Nine patients that had COVID-19 and were treated as outpatients were classified as group 1, 10 patients who were hospitalized due to COVID-19 were classified as group 2, and 10 patients who did not have COVID-19 and applied to the urology outpatient clinic with ED complaints and had similar clinical characteristics were classified as the control group (group 3). Patients underwent diagnostic evaluation including International Index of Erectile Function-5 form, penile color Doppler ultrasonography, corpus cavernosum electromyography, and fasting serum levels of reproductive hormones (07-11 am). According to the results of our study, cavernous smooth muscle damage occurs in patients with COVID-19 and it has an important role in the pathophysiology of erectile dysfunction.

NCT ID: NCT04864288 Completed - Clinical trials for To Investigate the Value of Penile Elastography in the Diagnosis of Fibrosis of CC

Value of Penile Elastography in Diagnosis of Patients With Erectile Dysfunction and Non-responders to Intra-corporal Injection

Start date: September 28, 2019
Phase:
Study type: Observational

Penile erection is a neurovascular response that induces penile arterial dilatation, increased blood flow, and cavernous smooth muscles (CSM) relaxation; the enlarging corpora cavernosa compress the subtunical veins, against a rigid tunica albuginea, and entrap blood within the penis. Impaired CSM function can result in corporo veno-occlusive dysfunction (CVOD) and erectile dysfunction. Nevertheless, diagnostic tests, which can evaluate the status of CSM, are not clinically applicable. Penile elastography is a new promising tool that can assess the stiffness of the corpora cavernosa. Accordingly penile elastography can assess the status of the cavernous tissue and can distinguish patient with corporal fibrosis.

NCT ID: NCT04801368 Completed - Clinical trials for Erectile Dysfunction

A Study to Analyze the Effects of Exparel for Post-Surgery Pain Control in Patients Undergoing Penile Prosthesis Placement

Start date: October 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this research is to determine the effects of penile ring block for local anesthesia with liposomal bupivacaine vs ropivacaine mixture in subjects undergoing surgery for Penile Prosthesis Placement.

NCT ID: NCT04720755 Completed - Clinical trials for Erectile Dysfunction

Low Intensity Extracorporeal Shock Wave Therapy (Li-ESWT) for Erectile Dysfunction

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Low-intensity extracorporeal shock wave therapy (Li-ESWT) has shown promise as a novel treatment for erectile dysfunction (ED), though the the mechanism of action and optimal protocol for administration has not been well-established. The aim of this study is to assess for subjective and objective improvements in erectile function following treatment with Li-ESWT.

NCT ID: NCT04662398 Completed - Clinical trials for Erectile Dysfunction

Using of Testes' Shocker in Improving Sexual Activity

Start date: December 5, 2020
Phase: N/A
Study type: Interventional

Using of testes' shocker in treating the sexual dysfunction.

NCT ID: NCT04491773 Completed - Clinical trials for Erectile Dysfunction Following Radical Prostatectomy

Study of Retinal and Choriocapillary Vascular Changes in Patients Undergoing Tadalafil 20mg for More Than 6 Months

Start date: November 1, 2019
Phase:
Study type: Observational

This study evaluates the retinal and choriocapillary vascular features in patients under the effects of Tadalafil 20mg for more than 6 months, using optical coherence tomography angiography.

NCT ID: NCT04488068 Completed - Prostate Cancer Clinical Trials

Transpelvic Magnetic Stimulation to Improve Urogenital Function

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

After recruitment, 20 male patients will be assigned 1:1 to either age-matched control (G1: sham) or age-matched intervention (G2: pelvic magnetic stimulation; TPMS) groups using computer-generated process, and baseline parameters will be established. All patients will be instructed by the investigators to perform standard of care pelvic floor exercise for the duration of the study. In addition, G2 patients will receive TPMS, while G1 patients will undergo sham treatment.

NCT ID: NCT04484090 Completed - Clinical trials for Erectile Dysfunction

Safety and Efficacy of Ohhmed Treatments for the Improvement of Erectile Dysfunction - A Feasibility Study

Start date: January 20, 2019
Phase: N/A
Study type: Interventional

Erectile dysfunction, the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance, is estimated to affect up to 30 million men in the United States. The disorder is age-associated. The available treatments include oral therapy, vacuum-constriction devices; shockwave therapy, intracavernosal injections of vasoactive agents, including alprostadil (prostaglandin E1, transurethral delivery of alprostadil, Implantation of penile prostheses. The OhhMed Company has developed the Vertica device that provides treatments for improvement of erectile function in patients with erectile dysfunction. This study assess the safety, efficacy, ease of use, and satisfaction of the Vertica device by men with mild to moderate erectile dysfunction.